However, despite its oncogenic effects and upregulation in several tumors, VAV3 expression is downregulated in certain cancers, including colon adenocarcinoma, head and neck squamous cell carcinoma, kidney cancer, lung adenocarcinoma, and prostate adenocarcinoma, as indicated by TCGA datasets. Here, VAV3 is linked to kidney cancer.